Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI | Zendy

Marcus Lind | Zendy; Arndís F. Ólafsdóttir | Zendy; Irl B. Hirsch | Zendy; Jan Bolinder | Zendy; Sofia Dahlqvist | Zendy; Aldina Pivodic | Zendy; Jarl Hellman | Zendy; Magnus Wijkman | Zendy; Erik Schwarcz | Zendy; Henrik Albrektsson | Zendy; Tim Heise | Zendy; William H. Polonsky | Zendy

Open Access

Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI

Author(s) -

Marcus Lind,

Arndís F. Ólafsdóttir,

Irl B. Hirsch,

Jan Bolinder,

Sofia Dahlqvist,

Aldina Pivodic,

Jarl Hellman,

Magnus Wijkman,

Erik Schwarcz,

Henrik Albrektsson,

Tim Heise,

William H. Polonsky

Publication year - 2020

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc20-1468

Subject(s) - medicine , hypoglycemia , diabetes mellitus , type 2 diabetes , insulin , type 1 diabetes , randomized controlled trial , distress , crossover study , endocrinology , placebo , alternative medicine , pathology , clinical psychology

Continuous glucose monitoring (CGM) reduces HbA 1c and time spent in hypoglycemia in people with type 1 diabetes (T1D) treated with multiple daily insulin injections (MDI) when evaluated over shorter time periods. It is unclear to what extent CGM improves and helps to maintain glucose control, treatment satisfaction, diabetes distress, hypoglycemic concerns, and overall well-being over longer periods of time.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research